# Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

> **NCT05228951** · PHASE2 · RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib maleate, dalpiciclib, Trastuzumab, letrozole

## Key facts

- **NCT ID:** NCT05228951
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-10
- **Primary completion:** 2022-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228951, "Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05228951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*